

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

				Complete if Known
				Application Number
				Filing Date
				First Named Inventor Bar-Or
				Art Unit 1649
				Examiner Name EMCH, GREGORY S
Sheet	1	of	9	Attorney Docket Number 4172-85

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	3,928,330	12/23/75	Ramey et al.	
	2	3,976,773	08/01/76	Curran	
	3	4,205,057	05/27/80	Whitaker	
	4	4,289,759	09/15/81	Heavner et al.	
	5	4,312,987	01/26/82	Beck	
	6	4,331,595	05/25/82	Heavner et al.	
	7	4,694,061	09/15/87	Pfeifer	
	8	4,694,081	09/15/87	MILLER ET AL.	
	9	4,806,538	02/21/89	Shimazaki et al.	
	10	4,940,709	07/10/90	Shimazaki et al.	
	11	4,992,552	02/12/91	Hubbs et al.	
	12	5,047,401	09/10/91	Lipsky et al.	
	13	5,358,938	10/25/94	Cai et al.	
	14	5,418,218	05/23/95	Wilber	
	15	5,434,151	07/18/95	Cai et al.	
	16	5,463,083	10/31/95	Biftu et al.	
	17	5,512,544	04/30/96	Wallach et al.	
	18	5,538,993	07/23/96	Mechoulam et al.	
	19	5,543,402	08/06/96	Bosies et al.	
	20	5,543,503	08/06/96	Chuntharapai et al.	
	21	5,545,404	08/13/96	Page	
	22	5,550,132	08/27/96	Benson et al.	
	23	5,578,323	11/26/96	Milstein et al.	
	24	5,648,486	07/15/97	Cai et al.	
	25	5,693,338	12/02/97	Milstein	
	26	5,700,804	12/23/97	Collins et al.	
	27	5,703,093	12/30/97	Cai et al.	
	28	5,741,809	04/21/98	Biftu et al.	
	29	5,750,530	05/12/98	Bryans et al.	
	30	5,750,565	05/12/98	Cai et al.	
	31	5,776,892	07/07/98	Counts et al.	
	32	5,780,503	07/14/98	Biftu et al.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

				<i>Complete if Known</i>	
		Application Number	10/679,699		
		Filing Date	10-02-2003		
		First Named Inventor	Bar-Or		
		Art Unit	1649		
		Examiner Name	EMCH, GREGORY S		
Sheet	2	of	9	Attorney Docket Number	4172-85

33	5,792,776	08/11/98	Biftu et al.	
34	5,817,751	10/06/98	Szardenings et al.	
35	5,834,032	11/10/98	Song	
36	5,843,950	12/01/98	Tasaka et al.	
37	5,856,323	01/05/99	Cai et al.	
38	5,877,174	03/02/99	Ono et al.	
39	5,883,227	03/16/99	Kline et al.	
40	5,886,152	03/23/99	Nakatani et al.	
41	5,919,785	07/06/99	Dinsmore et al.	
42	5,932,579	08/03/99	Campbell et al.	
43	5,976,569	11/02/99	Milstein	
44	5,985,581	11/16/99	Nixon et al.	
45	5,990,112	11/23/99	Campbell et al.	
46	6,034,057	03/07/00	Dutta	
47	6,034,221	03/07/00	Berezenko et al.	
48	6,060,452	05/09/00	Green et al.	
49	6,099,856	08/08/00	Milstein et al.	
50	6,107,050	08/22/00	Alkon et al.	
51	6,180,616	01/30/01	Fukunaga	
52	6,222,029	04/24/01	Edwards et al.	
53	6,248,363	06/19/01	Patel et al.	
54	6,262,119	07/17/01	Ferrante et al.	
55	6,265,535	07/24/01	Greene et al.	
56	6,395,774	05/28/02	Milstein	
57	6,441,172	08/27/02	Nefzi et al.	
58	6,541,224	04/01/03	Yu et al.	
59	6,677,473	01/13/04	Madison et al.	
60	6,689,765	02/10/04	Baroudy et al.	
61	6,967,202	11/22/05	Rao et al.	
62	2003/0153575	08/14/03	Orme et al.	
63	2003/0187226	10/02/03	GOODEY ET AL.	
64	2003/0225103	12/04/03	Bar-Or et al.	
65	2004/0038865	02/26/04	Gelber et al.	
66	2005/0096323	05/05/05	Cheng et al.	
67	2005/0119177	06/02/05	Bar-Or et al.	
68	2005/0249681	11/10/05	Heidenfelder et al.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet	3	of	9	Attorney Docket Number	4172-85
-------	---	----	---	------------------------	---------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² ; Number ⁴ ; Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	69	CS 254868	06/11/87	VANZURA JIRI RNDR CSC		
	70	DE 19937721	02/15/01	PLANCK GESELLSCHAFT		(partial translation)
	71	EP 0043219	01/06/82	ORTHO PHARMA CORP		
	72	EP 0216746	04/01/87	MONSANTO CO		
	73	EP 0493812	07/08/92	AJINOMOTO KK		
	74	EP 0557388	09/01/93	UNIV COMPANY PTY LTD		
	75	EP 0655060	05/31/95	XENOVA LTD		
	76	EP 610943	08/17/94	URIACH & CIA SA J		
	77	EP 939124	09/01/99	SMITHKLINE BEECHAM PLC		
	78	FR 2717484	09/22/95	PF MEDICAMENT		
	79	GB 2263109	07/14/93	BRITISH BIO TECHNOLOGY		
	80	JP 10-226615	08/25/98	POLA CHEM IND INC		(Translated Abstract)

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

Complete if Known

Application Number	10/679,699
Filing Date	10-02-2003
First Named Inventor	Bar-Or
Art Unit	1649
Examiner Name	EMCH, GREGORY S

Sheet	4	of	9	Attorney Docket Number	4172-85
-------	---	----	---	------------------------	---------

81	JP 10245315	09/14/98	VANZURA JIRI RNDR CSC	(translated abstract)
82	JP 2000327575	11/28/00	TEIKA SEIYAKU KK	(translated abstract)
83	JP 3176478	07/31/91	SNOW BRAND MILK PROD CO LTD	(translated abstract)
84	JP 63290868	11/28/88	FUJISAWA PHARMACEUTICAL CO	(translated abstract)
85	NZ 335544	08/31/01	NEURONZ LTD	
86	WO 02/062797	08/15/02	CELLTECH R & D INC	
87	WO 02/12201	02/14/02	DMI BIOSCIENCES INC	
88	WO 2000/057187	09/28/00	UNIV VANDERBILT	
89	WO 91/14378	10/03/91	NUTRASWEET CO	
90	WO 93/08815	05/13/93	CYTOVEN	
91	WO 94/04512	03/03/94	XENOVA LTD	
92	WO 94/04513	03/03/94	XENOVA LTD	
93	WO 94/04537	03/03/94	CYTOMED INC	
94	WO 94/20063	09/15/94	CYTOVEN INT NV	
95	WO 95/18610	07/13/95	CYTOMED INC	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

Complete if Known

Application Number	10/679,699
Filing Date	10-02-2003
First Named Inventor	Bar-Or
Art Unit	1649
Examiner Name	EMCH, GREGORY S

Sheet 5 of 9 Attorney Docket Number 4172-85

96	WO 96/00212	01/04/96	CYTOMED INC		
97	WO 96/00391	01/04/96	AFFYMAX TECH NV		
98	WO 96/10396	04/11/96	EMISPHERE TECH INC		
99	WO 97/12625	04/10/97	CYTOVEN J V		
100	WO 97/36888	10/09/97	MERCK & CO INC		
101	WO 97/48685	12/24/97	GLAXO GROUP LTD		
102	WO 99/40931	08/19/99	UNIV GEORGETOWN		
103	WO 99/49865	10/07/99	MAYO FOUNDATION		
104	WO 99/51720	10/14/99	CYTRAN LTD		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No. ¹	
	105	AKIYAMA ET AL., <i>Neurobiol. Aging</i> (2000), 21, pages 383-421
	106	Alvarez et al., "Isolation and Structure Elucidation of Two New Calpain Inhibitors from <i>Streptomyces Griseus</i> "; <i>J. Antibiotics</i> , 47(11):1195-1201 (November 1994)
	107	Arbabi et al., "Priming Interleukin 8 Production: Role of Platelet-Activating Factor and p38"; <i>Arch Surg.</i> , 134(12):1348-1353 (December 1999); 15pgs.
	108	Au et al., "Effect of PDE4 Inhibitors on Zymosan-Induced IL-8 Release From Human Neutrophils: Synergism with Prostanoids and Salbutamol"; <i>Br. J. Pharmacol.</i> , 123:1260-1266 (1998)

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet	6	of	9	Attorney Docket Number	4172-85
-------	---	----	---	------------------------	---------

109	Balk, "Lesson 24, Volume 12 – ARDS: Pathophysiology of SIRS and MODS" www.chestnet.org/education/pccu/vol12/lesson24.html, pp. 1-19, printed 7/20/2000
110	Barrow et al., WIN 64821, a New Competitive Antagonist to Substance P, Isolated from an Aspergillus Species: Structure Determination and Solution Conformation"; J. Org. Chem., 58:6018-6021 (1993)
111	Binisti et al.; "Structure-Activity Relationships in Platelet Activating Factor"; J. Lipid Mediat. Cell Signal; (January 1997); Vol. 15(2); pp. 125-144 (Abstract)
112	BRAUNS, et al., Anticancer Research 24:1713-20 (2004)
113	Chan et al., "Site-Specific N-Terminal Auto-Degradation of Human Serum Albumin"; Eur. J. Biochem., 227:524-528 (1995)
114	Cytokines and Autoimmune Diseases, edited by Kuchroo, et al., 2002, Humana Press Inc., Totowa, NJ, pages 3-23, 389-406
115	DATABASE WPI Section Ch, Week 199844 Derwent Publications Ltd., London, GB; Class B03, AN 1998-515050 XP002369751
116	Davidson et al. "Autoimmune Diseases", N. Engl. J. Med (2001) 345(5), pages 340-350
117	DIRR, K. ET AL: "The transformation of arginine into citrulline" Z. PHYSIOL. CHEM. , 237, 121-30, 1935
118	FADEN et al., J. Cerebral Blood Flow & Metabolism 23:355-63 (2003)
119	FADEN, et al., J. Alzheimer's Dis. 6:S93-S97 (2004)
120	FADEN, et al., J. Cerebral Blood Flow & Metabolism 23:342-54 (2003)
121	Gross et al., "Regulation of Interleukin-8 Production in a Human Colon Epithelial Cell Line (HT-29); Gastroenterology, 108:653-661 (1995)
122	Hayashi et al., "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 from Binding to and Activating Human Blood Neutrophils"; J. Immunol., 154:814-824 (1995)
123	ISHII, et al. Toxicology Letters, 7:433-37 (1981)
124	JACKSON I M D ET AL: "AMYOTROPHIC LATERAL SCLEROSIS TRH AND HISTIDYLPROLINE DIKETOPIPERAZINE IN THE SPINAL CORD AND CEREBROSPINAL FLUID" NEUROLOGY, vol. 36, no. 9, 1986, pages 1218-1223, XP008090473 ISSN: 0028-3878
125	KAAKKOLA SEPO; WURTMAN RICHARD J: "Effects of two diketopiperazines, cyclo (His-Pro) and cyclo (Asp-Phe), on striatal dopamine: A microdialysis study" BRAIN RESEARCH BULLETIN, vol. 32, no. 6, 1993, pages 667-672, XP002369690

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

				Complete if Known	
Sheet	7	of	9	Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
				Attorney Docket Number	4172-85

126	Kulikov et al., "Review: The Bioregulatory Role of Platelet-Activating Factor in Intracellular Processes and Cell – Cell Interactions", www.protein.bio.msu.su/biokhimiya/contents/v63/full/63010057.html, pp. 1-13 (1997)
127	McCAIN, et al. Int. J. Immunopharmacol. 8(4):443-46 (1986)
128	McCAIN, et al., Life Science, 41:169-76 (1987)
129	MeSH, "Autoimmune Diseases", internet document <> <http://www.ncbi.nlm.nih.gov/sites/entrez> >, accessed 10/31/07, 2 pages
130	Miller et al., "Peptide Inhibitor of Interleukin-8 (IL-8) Reduces Staphylococcal Enterotoxin-A (SEA) Induced Neutrophil Trafficking to the Lung"; Inflamm. Res., 45:393-397 (1996)
131	MILNE, et al. J. Pharm. Pharmacol., 50:1331-37 (1998)
132	Nitecki et al., J. Org. Chem., 33(2):864-866 (1968).
133	Palacios et al., "Tenidap Decreases IL-8 and Monocyte Chemoattractant Peptide-1 (MCP-1) mRNA Expression in the Synovial Tissue of Rabbits with Antigen Arthritis and in Cultured Synovial Cells"; Clin. Exp. Immunol., 111:588-596 (1998)
134	PRASAD C ET AL: "Increased cerebrospinal fluid cyclo(His-Pro) content in schizophrenia." NEUROPEPTIDES NOV 1991, vol. 20, no. 3, November 1991 (1991-11), pages 187-190, XP002477203 ISSN: 0143-4179
135	PURVES ET AL., Life: the Science of Biology, 3rd Ed. (1992), page 376
136	Rainger et al., "Endothelial-Borne Platelet-Activating Factor and Interleukin-8 Rapidly Immobilize Rolling Neutrophils"; Am. J. Physiol., 272(Heart Circ. Physiol. 41):H114-H122 (1997)
137	Rainsford et al., "Effects of 5-Lipoxygenase Inhibitors on Interleukin Production by Human Synovial Tissues in Organ Culture: Comparison with Interleukin-1-Synthesis Inhibitors"; J. Pharm. Pharmacol., 48:46-52 (1996)
138	Rotz et al., "Platelet-Activating Factor Exerts Mitogenic Activity and Stimulates Expression of Interleukin 6 and Interleukin 8 in Human Lung Fibroblasts via Binding to its Functional Receptor"; J. Exp. Med., 184:191-201 (1996)
139	SAKURADA et al. J. Pharm. Pharmacol., 34:750-51 (1982)
140	Sakuta et al., "Dual Regulatory Effects of Interferon- α , - β , and - γ on Interleukin-8 Gene Expression by Human Gingival Fibroblasts in Culture Upon Stimulation with Lipopolysaccharide from Prevotella Intermedia, Interleukin-1 α , or Tumor Necrosis Factor- α "; J. Dent Res., 77(8):1597-1605 (1998)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	8	of	9	Complete if Known
				Application Number
				10/679,699
				Filing Date
				10-02-2003
				First Named Inventor
				Bar-Or
				Art Unit
				1649
				Examiner Name
				EMCH, GREGORY S
				Attorney Docket Number
				4172-85

141	Sano et al. "Process Research and Development of L-Alanyl-L-Glutamine, a Component of Parenteral Nutrition", Organic Process Research & Development, 2000, Vol. 4, pages 147-152
142	Shimazaki et al., "Diketopiperazine Derivatives, a New Series of Platelet-Activating Factor Inhibitors"; Chem. Pharm. Bull., 35(8):3527-3530 (1987)
143	Shimazaki et al., "Diketopiperazines as a New Class of Platelet-Activating Factor Inhibitors"; J. Med. Chem., 30:1706-1709 (1987)
144	Shimazaki et al., "PAF Inhibitory Activity of Diketopiperazines: Structure-Activity Relationships"; Lipids, 26(12):1175-1178 (1991)
145	Smith et al., "Lesson 10, Volume 12 – Asthma: Evolving Anti-Inflammatory Therapy", www.chestnet.org/education/pccu/vol12/lesson10.html, pp. 1-8, printed 7/20/2000
146	Smith et al., Bioorg. Med. Chem., 8:2369-2374 (1998)
147	Smith et al., Darlington. Mult. Scler. (1999) 5, pages 110-120
148	t'Hart et al., "DDT (2004) 9(12), page 517-524
149	The Cytokine Handbook, edited by Thomson and Lotze, 4th edition, 2003 Academic Press, Volume I, London, UK, pages 167-199, 456-474, 567-601
150	The Cytokine Handbook, edited by Thomson and Lotze, 4th edition, 2003 Academic Press, Volume II, London, UK, pages 838-860 and 1189-1211
151	UNAL et al., Brain Research, 747(1):52-59 (1997)
152	WALTER et al. Proc. Natl. Acad. Sci. 72:
153	Yoshida et al., "PAF Inhibitors of Microbial Origin"; Prog. Biochem. Pharmacol., 22:68-80 (1988)
154	International Search Report for International (PCT) Patent Application No. PCT/US03/31226, mailed June 14, 2005 (Attorney's Ref. No. 4172-85-PCT)
155	International Preliminary Examination Report for International (PCT) Patent Application No. PCT/US03/31226, mailed November 29, 2005 (Attorney's Ref. No. 4172-85-PCT)
156	Examiner's First Report for Australian Patent Application No. 2003279761, mailed June 16, 2008 (Attorney's Ref. No. 4172-85-PAU)
157	Supplementary Partial European Search Report for European Patent Application No. 03773099, mailed May 6, 2008 (Attorney's Ref. No. 4172-85-PEP)
158	Examination Report for New Zealand Patent Application No. 539735, mailed May 10, 2006 (Attorney's Ref. No. 4172-85-PNZ)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
Sheet	9	of	9	Attorney Docket Number	4172-85

159	Examination Report for New Zealand Patent Application No. 542886, mailed November 28, 2007 (Attorney's Ref. No. 4172-84-PNZ)
160	Examination Report for New Zealand Patent Application No. 539735, mailed January 10, 2008 (Attorney's Ref. No. 4172-85-PNZ)
161	Examination Report for New Zealand Patent Application No. 539735, mailed May 20, 2008 (Attorney's Ref. No. 4172-85-PNZ)

Examiner Signature	/Gregory Emch/	Date Considered	12/08/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./